+ +

•  

   

     IHC-P analysis of pancreas tissue by RIPK3 antibody (P16040) IHC-P was performed using sections of the formalin-fixed paraffin-embedded pancreas tissue;Result: Endocrine cells and exocrine cells are positively stained at the cytoplasm.    

  
  

The Receptor-Interacting Protein Kinase 3 (RIPK3) antibody is a critical tool for studying necroptosis, a regulated form of inflammatory cell death distinct from apoptosis. RIPK3. a serine/threonine kinase, acts as a central mediator in this pathway. Upon activation by upstream signals (e.g., TNF receptor family ligands or pathogen sensors), RIPK3 forms a necrosome complex with RIPK1 or other adaptors, leading to phosphorylation of the pseudokinase MLKL. This triggers MLKL oligomerization, membrane permeabilization, and eventual cell rupture, releasing DAMPs that promote inflammation. Dysregulated necroptosis is implicated in pathologies including inflammatory diseases, neurodegeneration, and cancer.

RIPK3 antibodies are widely used to detect RIPK3 expression, localization, and post-translational modifications in tissues or cultured cells via techniques like Western blot, immunohistochemistry, or immunofluorescence. They also aid in elucidating RIPK3's role in disease models and therapeutic contexts, such as evaluating inhibitors targeting the necroptosis pathway. However, antibody specificity remains a concern due to homology between RIPK family members and variable expression levels across cell types. Recent studies also highlight RIPK3's non-necroptotic roles in apoptosis, inflammasome activation, and metabolic signaling, expanding its research relevance. Validated RIPK3 antibodies are thus essential for advancing understanding of cell death mechanisms and their clinical implications.